61,335 results match your criteria hcv

Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease.

Liver Int 2021 Sep 15. Epub 2021 Sep 15.

Liver Section, Gastroenterology Department, Hospital del Mar, Barcelona, Spain.

Background: Liver fibrosis and transient elastography (TE) correlation in hepatitis C virus (HCV)-infected patients with compensated advanced chronic liver disease (cACLD) after sustained virological response (SVR) is unknown.

Aims: To evaluate TE accuracy at identifying cirrhosis 3 years after HCV-eradication.

Methods: Prospective, multi-centric study including HCV-cACLD patients before direct-acting antivirals (DAA). Read More

View Article and Full-Text PDF
September 2021

Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.

J Viral Hepat 2021 Sep 15. Epub 2021 Sep 15.

Gut Group, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland.

The efficacy of direct acting antivirals (DAA) provides an excellent opportunity to scale up HCV diagnosis and treatment, achieving the WHO target of HCV elimination by 2030. However, HCV reinfection among people who inject drugs (PWID) remains a concern and may impede elimination efforts. We assessed reinfection rates among PWID across six specialised treatment pathways, following DAA-based and interferon-based therapies in Tayside, Scotland. Read More

View Article and Full-Text PDF
September 2021

Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys.

Clin Transplant 2021 Sep 15:e14485. Epub 2021 Sep 15.

Division of Nephrology & Hypertension, Department of Medicine, University of Utah, Salt Lake City, UT, USA.

Kidney transplantation (KT) from hepatitis C virus infected(HCV+) donors to HCV negative recipients achieve excellent graft function but have relatively higher rates of post-KT co-infections presumably due to prolonged HCV viremia in transmission-and-treat approach. Ezetimibe acts as an antagonist of Niemann-Pick C1-Like 1 receptor required for HCV entry and theoretically can reduce HCV viremia. However, no data is available to examine the role of ezetimibe as a bridge therapy between KT surgery and direct acting antiviral(DAA) initiation. Read More

View Article and Full-Text PDF
September 2021

Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy.

JHEP Rep 2021 Jun 18;3(3):100279. Epub 2021 Mar 18.

Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.

Background & Aims: Patients hospitalised because of mental illness often have risk factors for contracting HCV. Scaling-up HCV screening for all psychiatric inpatients as a case-detection strategy for viral elimination is underexplored. This study aimed to evaluate the cost-effectiveness of scaling-up HCV screening and treatment for psychiatry hospital admissions in Switzerland the current standard-of-care risk-based approach, where only those with a history of substance misuse disorder are offered testing. Read More

View Article and Full-Text PDF

Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).

EClinicalMedicine 2021 Oct 5;40:101116. Epub 2021 Sep 5.

Department of Internal Medicine I, University Hospital Frankfurt, Germany.

Background: De novo steatosis is the main criteria for non-alcoholic fatty liver disease (NAFLD), which is becoming a clinically relevant comorbidity in HIV-infected patients. This may be due to the HIV virus itself, as well as long-term toxicities deriving from antiretroviral therapy. Therefore, HIV infected patients require prevention and monitoring regarding NAFLD. Read More

View Article and Full-Text PDF
October 2021

MicroRNA profile and iron-related gene expression in hepatitis C-related hepatocellular carcinoma: a preliminary study.

Arch Med Sci 2021 12;17(5):1175-1183. Epub 2019 Jul 12.

Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.

Introduction: Hepatocellular carcinoma (HCC) is very difficult to diagnose, especially in its early stages. Non-invasive diagnostic and prognostic factors for this cancer are urgently needed. The purpose of our study was to investigate whether the microRNAs (miRNAs) regulating genes involved in iron homeostasis, whose disruption is a hallmark of HCC, offer potential as diagnostic or prognostic factors of HCV-related hepatocellular carcinoma. Read More

View Article and Full-Text PDF

FADS2-dependent fatty acid desaturation dictates cellular sensitivity to ferroptosis and permissiveness for hepatitis C virus replication.

Cell Chem Biol 2021 Sep 11. Epub 2021 Sep 11.

Natural Science Division, Ochanomizu University, Bunkyō-ku, Tokyo 112-8610, Japan; Institute for Human Life Innovation, Faculty of Core Research, Ochanomizu University, Bunkyō-ku, Tokyo 112-8610, Japan.

The metabolic oxidative degradation of cellular lipids severely restricts replication of hepatitis C virus (HCV), a leading cause of chronic liver disease, but little is known about the factors regulating this process in infected cells. Here we show that HCV is restricted by an iron-dependent mechanism resembling the one triggering ferroptosis, an iron-dependent form of non-apoptotic cell death, and mediated by the non-canonical desaturation of oleate to Mead acid and other highly unsaturated fatty acids by fatty acid desaturase 2 (FADS2). Genetic depletion and ectopic expression experiments show FADS2 is a key determinant of cellular sensitivity to ferroptosis. Read More

View Article and Full-Text PDF
September 2021

Late presentation for HCV care: time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).

Liver Int 2021 Sep 14. Epub 2021 Sep 14.

Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France.

Background & Aims: Late presentation for care of hepatitis C virus (HCV) infection - defined as having severe liver fibrosis when first consulting a specialist for HCV care - increases morbidity and mortality. Identifying the socio-behavioral correlates of late presentation is essential to improve HCV strategies to optimize HCV cascade of care. We investigated clinical and socio-behavioral correlates of late presentation for care in HCV mono-infected individuals. Read More

View Article and Full-Text PDF
September 2021

Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data.

PLoS Pathog 2021 Sep 14;17(9):e1009916. Epub 2021 Sep 14.

MIVEGEC, CNRS, IRD, Université de Montpellier - Montpellier, France.

Opioid substitution and syringes exchange programs have drastically reduced hepatitis C virus (HCV) spread in France but HCV sexual transmission in men having sex with men (MSM) has recently arisen as a significant public health concern. The fact that the virus is transmitting in a heterogeneous population, with different transmission routes, makes prevalence and incidence rates poorly informative. However, additional insights can be gained by analyzing virus phylogenies inferred from dated genetic sequence data. Read More

View Article and Full-Text PDF
September 2021

All cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.

J Gastroenterol Hepatol 2021 Sep 14. Epub 2021 Sep 14.

St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.

Background And Aims: Hepatitis C virus (HCV) cure with direct-acting antiviral (DAA) therapy improves survival in patients with HCV-related hepatocellular carcinoma (HCC). We hypothesised that HCV-HCC survival has increased in the DAA-era, more than other aetiologies of HCC. We aimed to evaluate survival following HCC diagnosis in the pre-DAA and DAA eras, across each aetiology of HCC. Read More

View Article and Full-Text PDF
September 2021

Development of a Novel Bioluminescence Pyrophosphate Assay for the High-Sensitivity Detection of Hepatitis B Virus.

Appl Biochem Biotechnol 2021 Sep 14. Epub 2021 Sep 14.

State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Si Pai Lou 2#, Xuanwu District, Nanjing, 210096, China.

The transmission of bloodborne viruses through transfusion remains a major blood supply-related safety concern, with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) being the most important pathogens in this context. Real-time bioluminescent pyrophosphate testing has been developed as a means of readily detecting bacterial cells within particular sample types without requiring the use of expensive or complex instrumentation. The sensitivity of this approach, however, is often limited such that it is not compatible with many potential applications. Read More

View Article and Full-Text PDF
September 2021

Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and studies.

Heliyon 2021 Sep 9;7(9):e07962. Epub 2021 Sep 9.

Center of Scientific Excellence for Infuenza Viruses, National Research Centre, 12622 Dokki, Giza, Egypt.

Drug repurposing is an important approach to the assignment of already approved drugs for new indications. This technique bypasses some steps in the traditional drug approval system, which saves time and lives in the case of pandemics. Direct acting antivirals (DAAs) have repeatedly repurposed from treating one virus to another. Read More

View Article and Full-Text PDF
September 2021

Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada.

Int J Drug Policy 2021 Sep 10:103439. Epub 2021 Sep 10.

CHUM Research Centre, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada. Electronic address:

Background: Frequent injecting increases hepatitis C (HCV) acquisition risk among people who inject drugs (PWID). However, few studies have examined how temporal fluctuations in injecting frequency may effect HCV infection risk. Thus, this study examined HCV incidence according to injecting frequency trajectories followed by PWID over one year in Montréal, Canada. Read More

View Article and Full-Text PDF
September 2021

Increased integrated testing for HIV, hepatitis C and sexually transmitted infections in health care facilities: results from the INTEGRATE Joint Action pilots in Lithuania, Romania and Spain.

BMC Infect Dis 2021 Sep 13;21(Suppl 2):845. Epub 2021 Sep 13.

Chelsea & Westminster Hospital NHS Foundation Trust, London, UK.

Background: Indicator condition guided HIV testing is a proven effective strategy for increasing HIV diagnosis in health care facilities. As part of the INTEGRATE Joint Action, we conducted four pilot studies, aiming to increase integrated testing for HIV/HCV/HBV and sexually transmitted infections, by introducing and expanding existing indicator condition guided HIV testing methods.

Methods: Pilot interventions included combined HIV/HCV testing in a dermatovenerology clinic and a clinic for addictive disorders in Lithuania; Increasing HIV testing rates in a tuberculosis clinic in Romania by introducing a patient information leaflet and offering testing for HIV/HCV/sexually transmitted infections to chemsex-users in Barcelona. Read More

View Article and Full-Text PDF
September 2021

Increasing integrated testing in community settings through interventions for change, including the Spring European Testing Week.

BMC Infect Dis 2021 Sep 13;21(Suppl 2):874. Epub 2021 Sep 13.

CHIP, Centre of Excellence for Health, Immunity and Infections,, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.

Background: Maximising access to testing by targeting more than one infection is effective in identifying new infections in settings or populations. Within the EU funded Joint Action INTEGRATE, this paper examined the feasibility and impact of expanding integrated testing for HIV, hepatitis C (HCV), chlamydia, gonorrhoea and/or syphilis in four community-based pilots through targeted interventions in Croatia, Italy and Poland and the Spring European Testing Week since community settings are key in detecting new infections and reaching key populations.

Methods: Pilots led by local INTEGRATE partners prioritised testing for other infections or key populations. Read More

View Article and Full-Text PDF
September 2021

[Current status of nucleic acid testing for hepatitis C].

Y Wang Y R Mao

Zhonghua Gan Zang Bing Za Zhi 2021 Aug;29(8):803-806

National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Nucleic acid testing is the gold standard for diagnosing HCV infection, and it is of great significance to guide the treatment of HCV patients and change the follow-up strategy. In recent years, its detection technology has become increasingly mature. This article summarizes the necessity and current status of nucleic acid testing for hepatitis C through the analysis of domestic and foreign literature, in order to provide reference for the formulation of relevant policies to eliminate hepatitis C in China. Read More

View Article and Full-Text PDF

[Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients].

Zhonghua Gan Zang Bing Za Zhi 2021 Aug;29(8):776-780

Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China.

To investigate the long-term characteristic changes of virus, immune status, and liver fibrosis markers in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients after receiving direct-antiviral agents (DAAs). HIV/HCV co-infected patients who visited the Guangzhou Eighth People's Hospital, Guangzhou Medical University from May 2014 to December 2019 were selected as the research subjects. The changes of virological response rate, peripheral blood CD4(+)T lymphocyte level and serological markers of liver fibrosis (APRI score and FIB-4 index) were observed during 144 weeks of follow-up course after the end of DAAs treatment. Read More

View Article and Full-Text PDF

Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections.

Transplant Direct 2021 Oct 7;7(10):e762. Epub 2021 Sep 7.

Transplant Institute, NYU Langone Health, New York, NY.

Transplanting hepatitis C viremic donor organs into hepatitis C virus (HCV)-negative recipients is becoming increasingly common; however, practices for posttransplant direct-acting antiviral (DAA) treatment vary widely. Protracted insurance authorization processes for DAA therapy often lead to treatment delays.

Methods: At our institution, 2 strategies for providing DAA therapy to HCV recipients of HCV transplants have been used. Read More

View Article and Full-Text PDF
October 2021

Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting.

Transplant Direct 2021 Oct 7;7(10):e761. Epub 2021 Sep 7.

Division of Kidney and Pancreas Transplantation, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN.

Transplantation of hepatitis C viremic (HCV+) deceased donor kidney transplants (DDKT) into aviremic (HCV-) recipients is a strategy to increase organ utilization. However, there are concerns around inferior recipient outcomes due to delayed initiation of direct-acting antiviral (DAA) therapy and sustained HCV replication when implemented outside of a research setting.

Methods: This was a retrospective single-center matched cohort study of DDKT recipients of HCV+ donors (cases) who were matched 1:1 to recipients of HCV- donors (comparators) by age, gender, race, presence of diabetes, kidney donor profile index, and calculated panel-reactive antibody. Read More

View Article and Full-Text PDF
October 2021

Editorial: Viral Hepatitis: Pathophysiology, Prevention, and Control.

Front Cell Infect Microbiol 2021 26;11:633580. Epub 2021 Aug 26.

University School of Biotechnology, Guru Gobind Singh Indraprastha University, New Delhi, India.

View Article and Full-Text PDF

Hepatitis C Virus Reactivation Following COVID-19 Vaccination - A Case Report.

Int Med Case Rep J 2021 29;14:573-576. Epub 2021 Aug 29.

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.

Purpose: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impacted morbidity and mortality during the pandemic of 2020-2021. A number of anti-COVID-19 vaccines have been developed with an unprecedented speed. While these vaccines have good efficacy and are safe, the experience with their use is limited and hence the knowledge of rare side effects. Read More

View Article and Full-Text PDF

Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia.

Infect Drug Resist 2021 3;14:3599-3608. Epub 2021 Sep 3.

Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are hepatotropic viruses whose primary replication occurs in the liver. Despite the significant clinical importance of early screening of hepatitis B and C virus infection in decreasing the hepatotoxicity effect of anti-tuberculosis drugs, screening of hepatitis B and C virus among tuberculosis (TB) patients before treatment has not been practiced in Ethiopia. Thus, this study was conducted to determine the seroprevalence and associated factors of HBV and HCV infections among pulmonary TB (PTB) patients attending health facilities in Gondar, Northwest Ethiopia. Read More

View Article and Full-Text PDF
September 2021

Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients.

Hum Antibodies 2021 Sep 3. Epub 2021 Sep 3.

Microbial Biotechnology Department, Division of Genetic Engineering and Biotechnology, National Research Centre, Dokki, Cairo, Egypt.

This study aimed to evaluate the prognostic value of baseline macrophage inflammatory protein (MIP)-1β/IL12p40 ratio for antiviral treatment outcome in HCV genotype 4 patients.

Methods: Sera of 450 treatment-naïve chronic HCV patients and 50 healthy individuals were collected. Liver transaminases, total bilirubin and albumin were biochemically tested, viral RNA was quantified, and circulating MIP-1β and IL-12p40 were estimated using human anti-MIP-1β and IL-12p40 antibodies in Sandwich ELISA. Read More

View Article and Full-Text PDF
September 2021

Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland.

Int J Drug Policy 2021 Sep 9:103434. Epub 2021 Sep 9.

Arud Centre for Addiction Medicine, Schützengasse 31, CH-8001 Zürich, Switzerland; Institute of Primary Care (IHAMZ), University Hospital Zurich, Switzerland.

Background And Aim: On-going risk-exposure followed by reinfection may jeopardize hepatitis C elimination efforts among people who use drugs. We estimated the HCV reinfection incidence in patients who successfully completed HCV therapy and attended a low-threshold access centre for comprehensive addiction medicine.

Methods: Retrospective chart review was undertaken, in a convenience sample of patients with opioid/cocaine use disorders who achieved sustained viral response (SVR) after direct-acting antiviral (DAA) therapy in Zurich, Switzerland between April 2015 and July 2019 (n = 153). Read More

View Article and Full-Text PDF
September 2021

Women in the 2019 hepatitis C cascade of care: findings from the British Columbia Hepatitis Testers cohort study.

BMC Womens Health 2021 Sep 13;21(1):330. Epub 2021 Sep 13.

British Columbia Centre for Disease Control, Vancouver, BC, Canada.

Background: Women living with hepatitis C virus (HCV) are rarely addressed in research and may be overrepresented within key populations requiring additional support to access HCV care and treatment. We constructed the HCV care cascade among people diagnosed with HCV in British Columbia, Canada, as of 2019 to compare progress in care and treatment and to assess sex/gender gaps in HCV treatment access.

Methods: The BC Hepatitis Testers Cohort includes 1. Read More

View Article and Full-Text PDF
September 2021

Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care.

Hepatol Commun 2021 Sep 1;5(9):1543-1554. Epub 2021 Jul 1.

Department of Pediatrics, Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, USA.

Amid the current US opioid crisis, hepatitis C virus (HCV) infection rates continue to rise in young adults, including among pregnant women, yet few studies describe linkage to care and treatment in pregnant or postpartum women with HCV infection. We used electronic health record data to estimate HCV treatment rates for postpartum women before (January 2014-September 2016) and during (October 2016-March 2018) implementation of a maternal-infant HCV linkage program in combination with a multidisciplinary clinic to colocate mother and infant care. Using Poisson regression models, we compared HCV treatment initiation rates, adjusting for demographics, substance use, and treatment. Read More

View Article and Full-Text PDF
September 2021

Health service utilisation and experiences of stigma among people who inject drugs in melbourne, australia.

J Viral Hepat 2021 Sep 12. Epub 2021 Sep 12.

Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Victoria, Australia.

While the testing and treatment of people who inject drugs (PWID) in Australia is a priority for local hepatitis C (HCV) elimination efforts, perceived stigma related to injecting drug use (IDU) has been identified as a major barrier for PWID engaging in health services. We used data from the EC Experience Cohort study to explore associations between IDU-related perceived stigma and the number of different health services accessed by PWID in Melbourne, Australia. Data from the baseline questionnaire were used. Read More

View Article and Full-Text PDF
September 2021

Primary biliary cholangitis has the highest waitlist mortality in patients with cirrhosis and acute on chronic liver failure awaiting liver transplant.

Clin Transplant 2021 Sep 12:e14479. Epub 2021 Sep 12.

Department of Biostatistics and Preventive Medicine, University of Texas Medical Branch, Galveston.

Background: Data are sparse on etiology specific outcomes on waitlist (WL) and post-transplant outcomes among patients with acute on chronic liver failure (ACLF).

Methods And Results: In a retrospective cohort of 14,774 adults from UNOS database listed for LT with cirrhosis and ACLF (01/2013-06/2019), 40% were due to alcohol-associated liver disease (ALD), followed by hepatitis C virus (HCV) at 20%, non-alcoholic steatohepatitis (19%), cryptogenic cirrhosis (7%), autoimmune hepatitis (5%), primary sclerosing cholangitis (PSC) at 3%, and 2% each for hepatitis B, primary biliary cholangitis (PBC), and metabolic etiology. Using competing risk analysis, cumulative risk of WL mortality was highest for PBC at 20. Read More

View Article and Full-Text PDF
September 2021

Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection.

Biomed J 2021 Sep 8. Epub 2021 Sep 8.

Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan; Department of Public Health and Biostatistics Consulting Center, Chang Gung University, Taoyuan, Taiwan. Electronic address:

Background: Thrombocytopenia is a common extrahepatic manifestation in chronic liver disease. However, there have been rare studies of impacts of risk for hepatitis C virus-associated thrombocytopenia (HCV-TP) and hepatitis B virus-associated thrombocytopenia (HBV-TP). The aim of this study is to evaluate different impacts of risk factors for HCV-TP and HBV-TP. Read More

View Article and Full-Text PDF
September 2021